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Manuscript received January 12, 2018 and accepted April 25, 2018AbstractChronic kidney disease (CKD) is a major risk factor for cardiovascular disease but is often associated with other risks such as dia-
betes and hypertension and can be both a cause and an effect of cardiovascular disease. Although epidemiologic data of an inde-
pendent association of reduced glomerular filtration rate with cardiovascular risk are strong, causative mechanisms are unclear.
Living kidney donors provide a useful model for assessing the ‘‘pure’’ effects of reduced kidney function on the cardiovascular
system. After nephrectomy, the glomerular filtration rate ultimately falls by about one-third so many can be classified as having
chronic kidney disease stages 2 or 3. This prompts concern based on the data showing an elevated cardiovascular risk with these
stages of chronic kidney disease. However, initial data suggested no increase in adverse cardiovascular effects compared with
control populations. Recent reports have shown a possible late increase in cardiovascular event rates and an early increase in left
ventricular mass and markers of risk such as urate and albuminuria. The long-term significance of these small changes is un-
known. More detailed and long-term research is needed to determine the natural history of these changes and their clinical sig-
nificance. J Am Soc Hypertens 2018;12(7):497–505. Crown copyright 2018 Published by Elsevier Inc. on behalf of American
Heart Association. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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In the United Kingdom, almost half of kidney transplants
are now from living kidney donors.1 The inevitable reduction
in kidney function after uninephrectomy raises the possibil-
ity of adverse cardiovascular effects given the graded associ-
ation of estimated glomerular filtration rate (eGFR) and
cardiovascular risk, which appears to begin at an eGFR ofrest: None.
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016/j.jash.2018.04.01060–75 mL/min/1.73 m2.2 At 5 years after donation, up to a
third of patients can be expected to have an eGFR of less
than 60 mL/min/1.73 m2 using the modification of diet in
renal disease or Chronic Kidney Disease Epidemiology
Collaboration equations.3
Detailed studies of donors show small but significant
structural and functional changes in the cardiovascular sys-
tem at 1 year after nephrectomy.4,5 In addition, a single but
carefully designed study appears to show a late rise in
adverse cardiovascular events.6 Studies of living kidney do-
nors appear to be a good approach to disentangling the
complex association of renal and cardiovascular disease al-
lowing important pathophysiological information on the
mechanisms of the association of chronic kidney disease
(CKD) and cardiovascular disease to be gained.
Mortality and Cardiovascular Events
Findings from multiple studies with up to 40 years of
follow-up have shown no evidence of reduced survivalalf of American Heart Association. This is an open access article
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ported better life expectancy (please see Supplementary
Table S1 online).7–11 Most are single-center reports and
describe health event rates far lower than the general pop-
ulation, although, importantly, the control data were often
derived from populations containing large numbers of sub-
jects who would not have been fit to donate.9 In an attempt
to overcome this, Garg et al.12 used a matched cohort study
to compare donor death and cardiovascular event rates with
the ‘‘healthiest general population’’ and excluded those
with conditions that would have precluded donation. Reas-
suringly, the combined end point of death and adverse car-
diovascular events was lower in donors than controls, and
the risk of cardiovascular events alone was not significantly
different.12 Further support comes from a large study using
US registry data comparing survival in over 80,000 donors
with that of a matched cohort of 9364 participants without
CKD drawn from the third National Health and Nutrition
Examination Survey (NHANES).7 Over a median follow-
up of 6.3 years, mortality among donors was not different
to controls stratified by age, sex, and race.7
There are a number of limitations of these studies. First,
the short durations of follow-up means that increased long-
term cardiovascular risk cannot be excluded. To date, most
studies have median follow-up periods of 6–8 years.7,12,13
Second, the influence of race on cardiovascular outcomes
after kidney donation is unclear. Most of the outcome
data are based on predominantly Caucasian populations
such as those in Canada and Norway.6,12 There is a need
for mortality studies on black, Hispanic, and Asian patients,
especially given the increased risk of hypertension in these
groups.
Concerns relating to possible long-term adverse effects
of donation arose in 2014 in an article examining 15-year
outcomes in 1901 Norwegian donors and 32,621 control
patients who were potentially eligible for donation.6 The
hazard ratios for all cause death (1.30 [95% confidential in-
tervals {CI} 1.11–1.52]), cardiovascular death (1.40 [95%
CI 1.03–1.91]), and end-stage renal disease (ESRD)
(11.38 [95% CI 4.37–29.63]) were significantly increased
in donors with curves diverging after about 10 years.6 Lim-
itations of this study include exclusion of marginal donors
with comorbidity such as obesity, an older donor group
(8 years) than controls, and longer follow-up of donors
compared with controls.6,14 In addition, the rural area of
Norway used to conduct the study has an unusually high
life expectancy, and most living kidney donors (including
all who developed ESRD with its attendant high cardiovas-
cular risk) were genetically related to the recipient.14
Nevertheless, these data are at least cause for concern and
should give rise to more intensive long-term follow-up of
donor populations around the world. It is impossible to
exclude with certainty that a reduction in glomerular filtra-
tion rate (GFR) of any cause, including donation, may lead
to an increase in adverse cardiovascular events.A major problem with studies using non-mortality end
points in living kidney donors is surveillance bias.13 Higher
rates of hypertension and proteinuria in donors may be a
result of more intensive medical review.13 Reese et al.13
found that donors made more visits to primary care and
had more diagnosed non-melanoma skin lesions; both find-
ings are suggestive of this form of bias. This reinforces the
need for well-controlled prospective studies of adequate
duration.Vascular ChangesHypertensionMost patients with CKD are hypertensive but it is not
clear if this is a universal finding when GFR is reduced.
There has been suspicion for many years that donors have
excess rates of hypertension and albuminuria but the
quality of evidence is poor and reports are inconsistent.15
A meta-analysis of 48 studies found that it was not
possible to assess the risk of hypertension requiring treat-
ment as none of the primary studies had an adequate sam-
ple size to detect a 1.5-fold increase in risk after donation
with at least 80% statistical power.16 Thus, change in
blood pressure (mm Hg) is frequently used as an interme-
diary marker for increased risk of hypertension.16 Of the
10 studies that had a control group and a follow-up of
over 5 years, there was an increase in blood pressure of
about 6 mm Hg systolic and 4 mm Hg diastolic when
compared with healthy adults with similar age, sex, and
ethnicity.16 Garg et al. also found that donors were
more likely to be diagnosed with hypertension (defined
using diagnostic codes on outpatient or discharge paper-
work) than controls (16.3% vs. 11.9%, hazard ratio 1.4);
however, there is a strong possibility of surveillance
bias.9
There are many flaws in these studies; most were retro-
spective and few used contemporaneous control groups
that were followed up in a similar way to donors.15 The
transplant community can be criticized for a lack of quality
prospective long-term studies of blood pressure in living
kidney donors but there are significant obstacles. Not
only are such studies expensive and difficult to perform,
particularly with respect to finding appropriate controls,
but live donor transplants are often carried out in large hos-
pital centers involving long traveling times.6,15 In Korea,
for example, just 11% of patients were followed up despite
over 80% of kidney transplantation in that country
involving live donors.17
Data from 24-hour ambulatory blood pressure studies are
mixed. In a prospective controlled observational study, Ka-
siske et al.18 found no statistical difference in ambulatory
blood pressure values or in night-time ‘‘dipping’’ at
36 months between 135 well-matched controls and 126 do-
nors. By contrast, data from 1214 donors in the mandatory
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Among initially normotensive donors, 43.1% developed
hypertension diagnosed by ambulatory blood pressure
monitoring within the 10-year follow-up period.15 Hyper-
tension was defined as a systolic of greater than 140mm
Hg and/or a diastolic of greater than 90 mm Hg or the
use of an antihypertensive medication.15 There was no con-
trol group, so conclusions are difficult to draw but using the
Framingham hypertension risk score, it was estimated that
by 12 months, nephrectomy had increased the risk of hyper-
tension by 3.64 times.15 The influence of race on rates of
hypertension and other morbidities requires much more
investigation. To date, the best data comes from a retrospec-
tive US study of 4650 living kidney donors.19 Postnephrec-
tomy events were compared with NHANES data from the
general population with a median follow-up of 7.7 years.19
Thirteen percent of the group were black and 8% Hispanic.19
The overall prevalence of hypertension at 5 years was 17.8%
but this was increased by 52% for blacks and 36% for His-
panics compared with white donors, exceeding what would
be expected in the general population in both Hispanic and
black patients over the age of 55 years.19 The definition of
hypertension was based on billing claims, pharmacy claims,
and antihypertensive drug category codes.19
In a number of studies, blood pressure variability rather
than blood pressure alone has been linked to cardiovascular
mortality and progression of renal disease.20,21 Ternes
et al.22 studied 193 donors and 196 controls as part of the
prospective Assessing Long-Term Outcomes in Living Kid-
ney Donors study. There was no difference in blood pres-
sure coefficient of variance 12 month after nephrectomy
compared with controls.22 In summary, despite years of
study, it is still not possible to draw safe conclusions on
whether the reduction in GFR caused by kidney donation
causes an increase in blood pressure. This may be because
there is no renal cortical damage or ischemia in kidney do-
nors; the circulating renin-angiotensin system is probably
not activated.4,5 This lack of association between living
kidney donors and increased risk of HTN benefits studies
investigating the influence of a reduced GFR on the cardio-
vascular system as it eliminates the possible confounding
effects of high blood pressure. The caveat, however, is
that if blood pressure is a major distinguishing feature be-
tween donors and patients with chronic kidney disease,
findings in kidney donors may not apply to those with
CKD.Pre-eclampsia and Gestational HypertensionPatients with CKD are at higher risk of developing
pre-eclampsia during pregnancy and at an increased
severity compared with controls.23 This is of impor-
tance with respect to long-term cardiovascular health
as pre-eclampsia confers a 12-fold increased future
risk of cardiovascular disease.24 Studies investigatingrisk of pre-eclampsia in living kidney donors are mainly
retrospective, observational, and reliant on patient self-
reporting. Ibrahim et al.25 reported on 1085 living
kidney donors with 3213 pregnancies. Pregnancies after
donation were associated with a lower rate of full-term
deliveries (73.7% vs. 84.6%).25 Donors also had higher
rates of gestational hypertension (5.7% vs. 0.6%) and
pre-eclampsia (5.5% vs. 0.8%) after donation than
before donation.25 Gestational hypertension was defined
as a need for treatment during pregnancy only (not
before or after).25 Maternal, fetal, and pregnancy out-
comes were, however, similar to the general population,
and the influence of patient bias recall cannot be dis-
counted.25 In a similar study, Reisaeter et al.26 also
used questionnaires to review over 100 living kidney
donors and found higher pre-eclampsia rates after dona-
tion than before (5.7 vs. 2.6%), although maternal age, a
major confounder, could not be entirely accounted for in
multivariable modeling due to the low event rate. As the
pregnancy complications were recorded by clinicians,
this data may be more accurate.26 In a retrospective
cohort study of 85 female living kidney donors and
131 pregnancies, Garg et al.27 matched donors with con-
trols in a 1:6 ratio for number of pregnancies, time to
pregnancy, age, income, and urban/rural background.
Gestational hypertension and pre-eclampsia (defined
by diagnostic codes after clinical assessment) were
more than twice as common in living kidney donors
than controls.27 In a systematic review by the Kidney
Disease Improving Global Outcomes work group, Slinin
et al.28 concluded that women of child-bearing age
should be informed of an increased risk as part of the
consent process. On current evidence, it appears that
kidney donation, like CKD, increases the risk of pre-
eclampsia.Arterial StiffnessPulse wave velocity (PWV) is the gold standard non-
invasive measure of aortic stiffness.29 It is elevated in
CKD and a strong predictor of cardiovascular risk in
CKD and a variety of other diseases.30 There are several
studies of the effects of kidney donation on arterial stiffness
but many are small uncontrolled pilot studies from which
safe conclusions cannot be drawn. Fesler et al.29 showed
no change in PWV or any other marker of arterial stiffness
in a study of 45 donors before and 1 year after donation
without a control group. By contrast, a cross-sectional
study of 101 Lebanese kidney donors demonstrated that
PWV was 10% higher than healthy controls with a similar
age and sex distribution (although not screened to be
‘‘donor eligible’’).31
It is estimated that the required sample size to adequately
power a study to determine a 0.4 m/s change in PWV is
over 350 patients per group.30 Because there are no studies
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tent. In 2012, the Effect of A Reduction in glomerular filtra-
tion rate after NEphrectomy on arterial STiffness and
central hemodynamics study began that has a prospective,
multicenter, controlled longitudinal design.30 There is an
ambitious aim of recruiting 400 donors and controls, which
would allow sufficient statistical power to detect very small
changes of the order of 0.2 m/s.30 The results are expected
in 2018.30
An alternative method of measuring arterial stiffness is to
use aortic distensibility, the change in cross-sectional area
(usually measured by cardiac magnetic resonance [CMR])
per unit change in pressure. This has been used in a number
of studies and is of prognostic value.4 In a prospective
controlled study, distensibility was reduced in donors
compared with controls at 12 months from nephrectomy.4
Reduced aortic distensibility has also been seen in patients
with early-stage CKD.32Cardiac Structure and FunctionSeveral studies have investigated whether human kidney
donation causes structural and functional change in the left
ventricle.4,5,33 Moody et al.4 studied 68 donors and 56
equally healthy controls (many of whom were worked up
for donation but did not donate). At 12 months, there was
an increase in left ventricular (LV) mass measured by
CMR in donors but not controls.4 Global circumferential
strain was also decreased indicating early changes in sys-
tolic dysfunction.4 There was no change in blood pressure
measured by ambulatory monitoring and no association be-
tween change in LV mass and changes in blood pressure.4
In a similar but uncontrolled and smaller study also using
CMR, Altmann et al.5 studied 23 living kidney donors
and found that LV mass had increased at 12 months without
change in office blood pressure. In a small cross-sectional
echocardiographic and CMR study, 15 Italian donors were
compared with age- and sex-matched healthy controls
from the United States at a median of 8.4 years (minimum
of 5 years) from donation.33 Most measures of LV geometry
and function were not different in donors and controls but
donors did exhibit abnormalities of LV apical rotation and
torsion.33 By contrast, Hewing et al. also studied 30 living
kidney donors at baseline and 12 months after donation us-
ing 2D speckle tracking echocardiography and found no sig-
nificant differences in left or right ventricular function.34
In summary, there are few studies investigating cardiac
structural and functional change after kidney donation.
The studies that do exist have small sample sizes. Current
evidence indicates that kidney donation results in small
changes in cardiac structure and function. Whether these
changes are sustained and are associated with an increase
in cardiovascular risk is not known. Well-controlled
follow-up studies with serial cardiac investigations are
required.35Biochemical ChangesTraditional well-established risk factors for cardiac dis-
ease have been investigated in living kidney donors
including the propensity to develop glucose intolerance,
lipids, and the level of proteinuria compared with controls.Lipids and Glucose ToleranceIn a prospective study of 182 donors compared with 173
controls (also suitable for donation), there was no significant
difference in lipid profiles including high-density cholesterol,
low-density cholesterol, triglycerides, or lipoprotein(a) at
3 years.18 The subjects also underwent both a Haemoglobin
A1c and ‘‘the homeostasis model assessment of insulin resis-
tance’’ (HOMA-IR).18 Although both increased over time,
there was no difference between the donors and controls.18ProteinuriaProteinuria is an independent risk factor for cardiovascu-
lar mortality in the general population and patients with
CKD.2 Recent studies have also demonstrated an increased
prevalence of microalbuminuria.4,15 Thiel et al.15 for
example found that albumin to creatinine ratio (ACR)
increased from 1.2  2.7 to 1.9  10.7 mg albumin/
mmol creatinine in donors, and the prevalence of microal-
buminuria increased from 4.8% to 10.4% over 10 years
with a strong association with the development of hyperten-
sion. Moody et al also found that donors had a significantly
raised prevalence of microalbuminuria compared with
healthy controls at 12 months (odds ratio, 3.8 [95% CI,
1.1–12.8]; P ¼ .04).4 This effect may be progressive; in a
3-year prospective study of living kidney donors and
matched controls, Kasiske found a gradual rise in ACR in
donors, which did not occur in controls.18Renin-Angiotensin-Aldosterone SystemThe importance of this system in CKD is emphasized by
the efficacy of aldosterone-converting enzyme (ACE inhib-
itor) and angiotensin receptor blocker drugs in the control
of hypertension and reduction in proteinuria and disease
progression.36 Although this is thought to be an important
mechanism of cardiovascular and renal damage in CKD,
it may be one of many pathological pathways. Living kid-
ney donors show no evidence of elevated concentrations of
circulating renin or aldosterone and yet have evidence of
cardiovascular damage including increased LV mass and
reduced aortic distensibility.4,33
Although circulating levels of renin and aldosterone have
not been identified, there is some evidence of intrinsic acti-
vation.37 Kendi et al. used a novel method of investigating
activation of the renin-angiotensin-aldosterone system in
living kidney donors by studying urinary angiotensinogen
before and after donation.37 Urinary angiotensinogen is
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sterone system activation and was five times higher at
12 months after donation compared with baseline.37 The
study however only included 20 patients, and there was
no control group.37Metabolic Bone AbnormalitiesIn a prospective controlled study, biochemical changes
were examined in 201 donors and 198 controls at 6 months
after donation.38 There was a large (23%) increase in para-
thyroid hormone (PTH) in this cohort; this increase was
confirmed by Moody et al. in their prospective study of
donors at 12 months.4 Parathyroid hormone may be an
important mediator of left ventricular hypertrophy (LVH).
It has been shown to be independently related to LVH in pa-
tients after aortic valve replacement, in patients with ESRD
on hemodialysis and in the general population.39–42
Fibroblast growth factor 23 (FGF23) also has an impor-
tant role in bone metabolism and rises significantly in
CKD.43 Concentrations of FGF23 are associated with
increased LV mass in patients with CKD and animal and
cellular work suggests a powerful hypertrophic effect on
the myocardium.44 Expression of FGF23 receptors increase
in the hearts of those with CKD and it is associated with
LVH.45 FGF23 has been found to increase both afterFigure 1. A comparison of donors and patients with CKD. Features in
mediators of cardiac disease.3–5,8,15,18,25–27,30,33,38,46–48,63,65,66 ACR, u
23; GFR, glomerular filtration rate; PTH, parathyroid hormone; RAAS
pro-brain natriuretic peptide.nephrectomy and compared with controls in a number of
donor studies4,46–48 although there are some inconsistencies
which may be related to the use of different assays.43,49
Klotho is a transmembrane protein associated with
FGF23 signaling.50 Soluble klotho is cleaved and released
into the circulation or urine.50 A reduction in a-klotho
occurs in early CKD and is associated with accelerated ag-
ing.43,49 A reduction in klotho is associated with cardiac re-
modeling and fibrosis.51 There have been two small studies
investigating the effect of kidney donation on a-klotho with
divergent results. Ponte et al. found an acute reduction in
circulating klotho levels after serial measurements at 0, 1,
2, and 3 days after donation in 27 living kidney donors.49Klo-
tho levels remained lower than baseline at both 180 and
360 days after donation but had risen since the immediate
postoperative period.49 In contrast to a cross-sectional study
of 35 subjects at 5 years after donation, Thorsen et al.43,49
found no difference compared with healthy controls. Taken
together, these studies suggest that klotho levels may decline
acutely after donation recovering to baseline in the long term
but further studies are needed to draw firm conclusions.43Uric AcidUric acid is a result of purinemetabolism and largely exists
as urate.52 Although it has a powerful role as an antioxidantcommon give us valuable mechanistic information for possible
rine albumin to creatinine ratio; FGF23, fibroblast growth factor
, renin-angiotensin-aldosterone system; NT-proBNP, N terminal
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pro-oxidant agent.52 It has been shown to impair endothelial
nitric oxide production and to cause inflammation and prolif-
eration in smooth muscle by the NF kappa B pathway.53,54
Over 70% of uric acid is excreted by the kidney and serum
concentrations are therefore almost invariably raised in pa-
tients with CKD.55 In large population studies, elevated
uric acid is associated with both hypertension and adverse
cardiovascular outcomes.56–59 It is therefore unsurprising
that there is increasing interest in its role as a possible caus-
ative agent in the development of cardiovascular disease in
patients with CKD. Although cause and effect has been diffi-
cult to establish, the importance of the role of uric acid is that
it is a potentially modifiable risk factor.60,61 Kao et al.60
showed that allopurinol reduced LV mass and improved
both endothelial dysfunction and arterial stiffness in patients
with early-stage CKD. Long-term use of allopurinol also
improved both endothelial function and eGFR in patients
with CKD.62 A recent meta-analysis of 16 trials concluded
that uric acid–lowering therapy has a positive effect on
both kidney function and also reduced cardiovascular
events.61
In kidney donors at 1, 2, and 3 years, serum uric acid was
elevated compared with controls meeting criteria for dona-
tion.4,18 In a small prospective cohort study of 20 living kid-
ney donors, uric acid levels decreased immediately after
nephrectomy only to subsequently rise and remain high
throughout the 12-month study.37 Over the long term, donors
are more likely than controls to be newly diagnosed with
gout and to be commenced on treatment with allopurinol
or colchicine.63 In a small study of 42 living kidney donors,
uric acid correlated with indoxyl sulfate and p-cresyl
sulfate.64 These uremic toxins have potential importance as
they have been found to be associated with increases in ca-
rotid intimal thickness and markers of endothelial dysfunc-
tion in donors.64Novel Cardiovascular BiomarkersA variety of other biomarkers of cardiac disease have
been found to be deranged in CKD and associated with car-
diac events, death, and renal progression.46,65 The data
examining these biomarkers in donors are summarized on-
line (please see Supplementary Table S2 online).
Conclusion
Although there is evidence of an increase in long-term
cardiovascular risk in living kidney donors from a single
article,6 other studies have found no such effect, and further
high-quality work is urgently required. Reassuringly, if the
risk is increased, the level of this increase in risk is small
with absolute risks remaining much lower than those of
the general population.12 Effects on blood pressure and
risk of hypertension remain uncertain but there is evidencefrom more than one study of changes in cardiac and
vascular structure and function. As there was no change
in blood pressure in these studies it appears likely that
circulating factors associated with a decline in kidney func-
tion cause hypertrophic effects on the myocardium. Possi-
bilities include uric acid, PTH, and FGF23, but the
changes after donation are complex, and there may be other
influences. Consequently, kidney donors have already
provided us with valuable insights into the pathophysiology
of cardiorenal disease by allowing examination of the
isolated effects of a reduction in GFR (see Figure 1 for a
diagrammatic summary).
These intriguing data have prompted several groups
worldwide to enroll kidney donors in further prospective
studies. The possibility of investigating causal mechanisms
by using specific pharmacologic interventions in willing
volunteer donor subjects arises. This might provide
valuable mechanistic information on mediators of cardiac
disease in those with CKD.Acknowledgments
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Table S1
Summary of mortality studies in kidney donors
Reference Date Patient Numbers Control Group Matched Controls? Follow up Ethnicity/Age of
Donors
Single
Center?
Outcome Mortality
in Donors*
Garg.9 2008 Donors ¼ 1278
Controls ¼ 6359
Health administration
data
Yes—age, sex,
income, and number
of physician visits.
Mean 6.2 y. 92% Caucasian
5% Asian
<3% black
Canada
No No differences in
either mortality or
cardiovascular
disease events (1.3%
vs. 1.7%; hazard
ratio 0.7)
–
Ibrahim.8 2009 Donors ¼ 3698 Life table data Yes—age, sex, and
race.
255 matched 1:1
40 y. United States Yes Survival was similar to
controls
–
Segev.7 2010 Donors ¼ 80,347
Controls ¼ 9364
Third cohort of
National Health and
Nutrition
Examination Survey
(NHANES III)
Yes—1:1 based on
comorbidities.
Median 6.3 y. 13.1% black
12.3% Hispanic
United States
No Mortality among
donors was no
higher than controls
even when stratified
by age, sex, and race
–
Mjoen.10 2012 Donors ¼ 2269
Controls ¼ 6807
General population
statistics
Yes—Age, gender, and
year of birth. 3:1
match
Median 14.3 y. Mean age 47 y
41% male
Norway
Yes Both overall and
cardiovascular
mortality was lower
for donors
˅
Garg.12 2012 Donors ¼ 2028
Controls ¼ 20,280
‘‘Healthiest general
population’’
Excluded those
conditions that
precluded donation.
Yes—age, sex,
income, and
residence
10:1 match
Median 6.5 y. Median age 43 y.
Likely Caucasian,
Ontario, Canada
Yes Risk of death or major
cardiovascular
events was lower in
donors with a hazard
ratio of 0.66.
˅
Reese.13 2014 Donors ¼ 3368
Controls ¼ 3368
Healthy older patients
in the Health and
Retirement Study
Yes—based on patient-
reported health
Median 7.8 y. Mean age 59 y
Only 7% black
41% male
United States
No Donors were not at an
increased risk of
death or
cardiovascular
disease.
–
Mjoen.6 2014 Donors ¼ 1901
Controls ¼ 32,621
Health Study of Nord-
TrØndelag (HUNT)
population study.
No—controls were
considered fit to
donate.
Median 15.1 y. Mean age 46 y
All Caucasian
Norway
Yes Increased risk of all-
cause and
cardiovascular death
^
Rizvi.11 2016 Donors ¼ 90
Controls ¼ 90
Siblings of donors Yes—siblings paired. Mean 5.8 y. Mean age 37 y
70% male
Pakistan
Yes No difference in rates
of ischemic heart
disease
–
– No difference, ^ increase, ˅ decrease.
* Symbol indicating results seen in donors.
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Table S2
Cardiac biomarkers in LKD
Reference Date Population Study Numbers Control Group Study Type Outcome In Donors*
Markers of Inflammation
C-Reactive Protein (CRP)
Kielstein.65 2011 LKD Donors ¼ 24 No controls Cross-sectional. 1,
6, 12, 24, 72, and
168 h after
nephrectomy
Increase
postoperatively
significantly at
6 h. Peaked at
3 d and then
began to decline.
Still above
baseline at 7 d
after
nephrectomy.
^
Huan.46 2013 LKD Donors ¼ 34 No controls Longitudinal.
Baseline and
6 mo
No significant
difference
between baseline
and 6 mo.
–
Kasiske.38 2013 LKD and Healthy
control
Donors ¼ 201
Controls ¼ 198
Healthy siblings of
LKD approached
first. Healthy
controls meeting
LKD criteria.
Prospective.
Observational
cohort study.
Baseline and
6 mo.
No difference
between donor
and controls
–
Moody.4 2015 LKD and healthy
controls
Donors ¼ 68
Controls ¼ 56
Healthy controls
meeting LKD
criteria
Longitudinal.
Baseline and
12 mo.
Multicenter.
Increased serum
high sensitivity
CRP in donors
compared with
controls at 12 mo
1.90 vs. 1.00 mg/
dL.
^
Interleukin-6 (IL-6) and Tumour Necrosis Factor Alpha (TNFa)
Kielstein.65 2011 LKD Donors ¼ 24 No controls Cross-sectional. 1,
6, 12, 24, 72, and
168 h after
nephrectomy
Increases before
CRP. Elevated at
1 h
postoperatively
then began to
decline. Still
about baseline at
7 d after
nephrectomy.
^
Huan.46 2013 LKD Donors ¼ 34 No controls Longitudinal.
Baseline and
6 mo
No significant
difference in IL-
6 or TNFa after
donation.
–
Markers of Myocardial Fibrosis and Left Ventricular Hypertrophy
N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP)
Bellavia.33 2015 LKD Donors ¼ 15
Controls ¼ 15
Italian donors. US
age- and gender-
matched
controls.
Cross-sectional.
Measurements at
least 5 y after
donation.
No difference
between donors
and controls
–
Moody.4 2015 LKD and healthy
controls
Donors ¼ 68
Controls ¼ 56
Healthy controls
meeting LKD
criteria
Prospective,
longitudinal.
Baseline and
12 mo.
Multicenter.
No difference
between donors
and controls.
–
(continued on next page)
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Table S2 (continued )
Reference Date Population Study Numbers Control Group Study Type Outcome In Donors*
Altmann.5 2017 LKD Donors ¼ 23 No controls Prospective, cohort
study. Baseline,
4 mo and 12 mo.
No difference after
donation.
–
Aldosterone and Angiotensin II
Bellavia.33 2015 LKD Donors ¼ 15
Controls ¼ 15
Italian donors. US
age- and gender-
matched
controls.
Cross-sectional.
Measurements at
least 5 y after
donation.
No difference in
either
aldosterone or
angiotensin II
between donors
and controls
–
Moody.4 2015 LKD and healthy
controls
Donors ¼ 68
Controls ¼ 56
Healthy controls
meeting LKD
criteria
Prospective,
longitudinal.
Baseline and
12 mo.
Multicenter.
No difference in
aldosterone
between donors
and controls.
–
Renin
Bellavia.33 2015 LKD Donors ¼ 15
Controls ¼ 15
Italian donors. US
age- and gender-
matched
controls.
Cross-sectional.
Measurements at
least 5 y after
donation.
No difference
between donors
and controls.
–
Moody.4 2015 LKD and healthy
controls
Donors ¼ 68
Controls ¼ 56
Healthy controls
meeting LKD
criteria
Prospective,
longitudinal.
Baseline and
12 mo.
Multicenter.
No difference
between donors
and controls.
–
High-Sensitivity Troponin
Moody.4 2015 LKD and healthy
controls
Donors ¼ 68
Controls ¼ 56
Healthy controls
meeting LKD
criteria
Prospective,
longitudinal.
Baseline and
12 mo.
Multicenter.
Increase in
detectable serum
hs-cTnT5 ng/L
in donors 21%
vs. 2%
^
a-Klotho
Ponte.49 2014 LKD Donors ¼ 27 No controls Cross-sectional,
observational. 0,
1, 2, 3, 180, and
360 d after
donation.
Circulating klotho
levels remained
lower over a
sustained period.
˅
Thorsen.43 2016 LKD
CKD stage
healthy controls
Donors ¼ 35
CKD 3 ¼ 22
CKD 4 ¼ 18
CKD 5 ¼ 20
Controls ¼ 35
Colleagues and
friends of the
authors.
Cross-sectional,
observational,
single-center.
No difference
between donors
and controls.
Lower levels
seen in patients
with advancing
CKD.
–
Fibroblast Growth Factor 23 (FGF23)
Young.48 2012 LKD Donors ¼ 198
Controls ¼ 98
Known to the LKD.
Health status
based on patient
recall.
Cross-sectional.
Multi-center.
Serum FGF23 was
increased in
donors compared
with controls
(38.1 vs 29.7 pg/
mL).
^
Huan.46 2013 LKD Donors ¼ 34 No controls Prospective,
longitudinal.
Baseline and
6 mo.
FGF23 levels
increased at
6 mo compared
with baseline
^
(continued on next page)
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Table S2 (continued )
Reference Date Population Study Numbers Control Group Study Type Outcome In Donors*
54.0  27.9 RU/
mL vs.
70.0  32.9 RU/
mL.
Ponte.49 2014 LKD Donors ¼ 27 No controls Cross-sectional,
observational. 0,
1, 2, 3, 180, and
360 d after
donation.
No change
significantly
after donation.
At 180 d, there
was no change in
FGF23 levels
compared with
baseline.
–
Moody.4 2015 LKD and healthy
controls
Donors ¼ 68
Controls ¼ 56
Healthy controls
meeting LKD
criteria
Prospective,
longitudinal.
Baseline and
12 mo.
Multicenter.
Increase
significantly
from 67–84 RU/
mL after
donation.
^
Thorsen.43 2016 LKD
CKD stage
healthy controls
Donors ¼ 35
CKD 3 ¼ 22
CKD 4 ¼ 18
CKD 5 ¼ 20
Controls ¼ 35
Colleagues and
friends of the
authors.
Cross-sectional,
observational,
single-center.
Nonsignificantly
higher in donors
compared with
controls.
Increased as
renal function
deteriorated.
–
Kasiske.47 2016 LKD Donors ¼ 182
Controls ¼ 173
Matched controls Prospective,
longitudinal.
Baseline, 6 mo
and 36 mo after
donation.
Serum FGF23
levels at 6 and
36 mo were
higher than
controls.
^
Amino-Terminal Peptide of Procollagen III (PIIINP) and Procollagen Type I N Terminal Propeptide (PINP)
Bellavia.33 2015 LKD Donors ¼ 15
Controls ¼ 15
Italian donors. US
age- and gender-
matched
controls.
Cross-sectional.
Measurements at
least 5 y after
donation.
Elevated PIIINP
levels seen in
donors 5.8 (5.4–
7.6) mg/L vs. 1.1
(0.9–1.3)mg/dL.
^
Kasiske.47 2016 LKD Donors ¼ 182
Controls ¼ 173
Matched controls Prospective,
longitudinal.
Baseline, 6 mo
and 36 mo after
donation.
PINP
concentrations
were higher at
6 mo than paired
normal controls
(24.3% and
8.9%). No
difference at
36 mo.
^
Altmann.5 2017 LKD Donors ¼ 23 No controls Prospective, cohort
study. Baseline,
4 mo and 12 mo.
Increase in PIIINP
donors seen at
12 mo
0.45  0.11 ng/
mL vs.
0.56  0.14 ng/
mL
^
LKD; living kidney donors.
– No difference, ^ increase, ^ decrease.
 Klotho is a transmembrane protein associated with FGF23 signaling.
 Procollagen type III N-terminal is involved in fibroblast activation.
 Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone important in phosphate homeostasis, elevated early in CKD, and
recently implicated as a cause of left ventricular hypertrophy in CKD in a series of animal and human studies.1
* Symbol indicating results seen in donors.
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